Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies

Epidermal growth factor receptor (EGFR) mutations are common oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine kinase inhibitors (TKIs) is beneficial for patients with advanced and early-stage NSCLC. With the development of next-generati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenqian, Bai, Rilan, Guo, Hanfei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686611/
https://www.ncbi.nlm.nih.gov/pubmed/37369640
http://dx.doi.org/10.1097/CM9.0000000000002548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686611/
https://www.ncbi.nlm.nih.gov/pubmed/37369640
http://dx.doi.org/10.1097/CM9.0000000000002548

Ejemplares similares